{'52WeekChange': 'Infinity',
 'SandP52WeekChange': None,
 'address1': '139 Main Street',
 'address2': 'Suite 301',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 29,
 'askSize': 800,
 'averageDailyVolume10Day': 195787,
 'averageVolume': 129731,
 'averageVolume10days': 195787,
 'beta': None,
 'beta3Year': None,
 'bid': 28,
 'bidSize': 800,
 'bookValue': -17.923,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 28.15,
 'dayLow': 26.51,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -16.253,
 'enterpriseToRevenue': None,
 'enterpriseValue': 622888064,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 36.46943,
 'fiftyTwoWeekHigh': 46.25,
 'fiftyTwoWeekLow': 17.63,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 15842726,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 37,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.03907,
 'heldPercentInstitutions': 0.71667,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/blackdiamondtherapeutics.com',
 'longBusinessSummary': 'Black Diamond Therapeutics, Inc., a precision '
                        'oncology medicine company, discovers and develops '
                        'small molecule, tumor-agnostic therapies. Its lead '
                        'product candidate is BDTX-189, an inhibitor of '
                        'non-canonical and oncogenic mutations of ErbB kinases '
                        'epidermal growth factor receptor (EGFR) and '
                        'tyrosine-protein kinase. The company is also '
                        'developing allosteric-EGFR mutation inhibitors; and '
                        'various early stage pipeline programs targeting '
                        'allosteric mutations in kinases related to cancer '
                        'and/or rare genetic diseases. The company was '
                        'formerly known as ASET Therapeutics, Inc. and changed '
                        'its name to Black Diamond Therapeutics, Inc. in '
                        'January 2018. Black Diamond Therapeutics, Inc. was '
                        'founded in 2014 and is headquartered in Cambridge, '
                        'Massachusetts.',
 'longName': 'Black Diamond Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 979643904,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_424913244',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -43575000,
 'nextFiscalYearEnd': 1640908800,
 'open': 28.15,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617-252-0848',
 'previousClose': 26.99,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 28.15,
 'regularMarketDayLow': 26.51,
 'regularMarketOpen': 28.15,
 'regularMarketPreviousClose': 26.99,
 'regularMarketPrice': 28.15,
 'regularMarketVolume': 188795,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 35910700,
 'sharesPercentSharesOut': 0.0922,
 'sharesShort': 3312336,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2630075,
 'shortName': 'Black Diamond Therapeutics, Inc',
 'shortPercentOfFloat': 0.1383,
 'shortRatio': 21.7,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'BDTX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -13.874,
 'twoHundredDayAverage': 34.072033,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '822eae7d-25a2-3ffc-8b26-04730bb0212d',
 'volume': 188795,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.blackdiamondtherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02142'}